1. Home
  2. GAME vs AYTU Comparison

GAME vs AYTU Comparison

Compare GAME & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GameSquare Holdings Inc.

GAME

GameSquare Holdings Inc.

HOLD

Current Price

$0.42

Market Cap

26.6M

Sector

N/A

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.60

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAME
AYTU
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
25.7M
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
GAME
AYTU
Price
$0.42
$2.60
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
8.6M
39.9K
Earning Date
04-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
65.14
N/A
EPS
N/A
N/A
Revenue
$44,999,302.00
$27,632,080.00
Revenue This Year
$81.45
N/A
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.24
$0.98
52 Week High
$2.87
$3.07

Technical Indicators

Market Signals
Indicator
GAME
AYTU
Relative Strength Index (RSI) 74.16 52.34
Support Level $0.40 $2.46
Resistance Level $0.48 $2.66
Average True Range (ATR) 0.04 0.12
MACD 0.02 -0.01
Stochastic Oscillator 78.45 50.87

Price Performance

Historical Comparison
GAME
AYTU

About GAME GameSquare Holdings Inc.

GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: